On June 24, WuXi AppTec rose 3.36% in regular trading, trading at 135.2 HKD/share, with turnover of 44.19 million HKD.

On the news front, the company recently completed its H-Share Award Trust Plan with approximately 2.5 billion HKD in share repurchases, accumulating roughly 20.15 million H-shares representing about 0.68% of total share capital. Simultaneously, since June 12, the company has been executing a nearly 1 billion RMB A-share buyback program at a pace of approximately 100 million RMB per day, with repurchased shares designated for employee stock ownership plans. Additionally, the company has filed a lawsuit against the U.S. Department of Defense over its erroneous inclusion on a military-related entity list, actively defending its rights.

The broader innovative drug sector continues to warm up, with sector peers GenScript Biotech rising 3.86%, WuXi XDC up 2.95%, and WuXi Biologics gaining 1.61%, reflecting gradual restoration of industry confidence.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)